Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a report issued on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

The stock has a 50 day moving average price of $3.94 and a 200-day moving average price of $4.54. The stock has a market cap of $3.47 million, a P/E ratio of -2.40 and a beta of 1.13. Organovo has a twelve month low of $1.56 and a twelve month high of $21.96.

Organovo (NASDAQ:ONVO) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($2.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.52) by $0.24. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Analysts expect that Organovo will post -0.77 EPS for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.